Koshinski Asset Management
CNCR

Koshinski Asset Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Koshinski Asset Management’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-750
Closed -$13.5K – 820
2022
Q1 		$13.5K Sell
750
-200
-21% -$3.8K ﹤0.01% 1525
2021
Q4 		$22.6K Hold
950
– – ﹤0.01% 1404
2021
Q3 		$28.8K Buy
+950
New +$28.7K ﹤0.01% 1325

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Koshinski Asset Management's CNCR Position: Q2 2022 in Review

Koshinski Asset Management sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2022, closing a stake of 750 shares — an estimated $13.5K sold.

Koshinski Asset Management first reported a position in CNCR in Q3 2021 and held it in 3 quarters. The position peaked at $28.8K in Q3 2021. 20 funds tracked by Wall St. Rank hold CNCR as of Q2 2022.

  • Koshinski Asset Management reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2022 after selling out during the quarter.
  • Koshinski Asset Management sold 750 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2022, an estimated $13.5K.
  • Koshinski Asset Management first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q3 2021 and held it in 3 quarters.
  • Koshinski Asset Management's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $28.8K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2022.

Based on Koshinski Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.